Sanara Medtech, Inc. (SMTI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$35.03-0.06%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Sanara Medtech is growing revenue from $23.4M to $27.8M in Q1 2026. Operating income rose from $0.8M to $2.6M, showing better cost control. Gross profit improved by $4.3M, reflecting pricing and efficiency gains. The company aims for $118.5M revenue in 2026, moving toward profitability.
Sanara Medtech has missed earnings repeatedly and remains loss-making. The turnaround may stall if revenue growth slows or costs rise. The termination of a key agreement signals risks to strategic progress.
The price is about 22% below our fair value near $32. Analysts expect 15.5% revenue growth. Our view aligns with this but sees risk in execution and profitability.
Breaks if: Gross profit falls below $22M in next 4 quarters
Maintain and improve gross profit margins through product mix and revenue growth in surgical products.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on revenue expansion in the healthcare sector. The current thesis state reflects a mix of strong recent performance but fragile earnings quality and elevated near-term risks.
The market appears to price in a level of fragility due to weak execution quality, but this is somewhat justified given the company's recent performance. SMTI is currently valued as cheap compared to its peers, indicating an expectations gap.
Management has prioritized increasing revenue growth, which has shown positive results, but operating income remains mixed. The elevated risk of a near-term earnings miss, given the history of misses, adds uncertainty to the fundamental outlook.
The future performance of SMTI hinges on management's ability to maintain revenue growth while improving operating income and gross profit margins. Additionally, external factors like sector performance and economic indicators will play a crucial role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a miss. This miss raises concerns about management's execution. There are no new supportive factors to offset this.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Gross margin improved from 92% in 2025-Q2 to 93% in 2026-Q2 and similarly in Q1. Gross profit increased by $2.3 million year-over-year in Q2 2026. Management's focus on product mix and revenue growth is reflected in stable to improving gross margins, indicating delivery on this priority.
“Gross profit of $26.2 million, or 93% of net revenue, compared to gross profit of $23.9 million, or 92% of net revenue, in the second quarter of 2025.”
“Gross profit of $25.9 million, or 93% of net revenue, compared to $21.6 million, or 92% of net revenue, in the first quarter of 2025.”
Breaks if: Operating income falls below $1.5M in next 4 quarters
Focus on increasing operating income through revenue growth and managing operating expenses despite SG&A increases.
Stated as a priority in 2 of last 2 quarters. Operating income declined from $2.5 million in 2025-Q2 to $1.8 million in 2026-Q2 but improved year-to-date from $3.3 million to $4.4 million. Management acknowledges higher SG&A expenses but operating income trajectory year-to-date is improving, showing partial delivery on this priority.
“Operating income of $1.8 million, compared to operating income of $2.5 million in the second quarter of 2025.”
“Operating income of $2.6 million, compared to operating income of $0.8 million in the first quarter of 2025.”
Breaks if: Revenue falls below $110M in FY26
Continue driving double-digit net revenue growth primarily through expanding sales of soft tissue repair products and market penetration.
Stated as a priority in 2 of last 2 quarters. Net revenue grew from $25.8 million in 2025-Q2 to $28.1 million in 2026-Q2 (+9% YoY) and increased 14% year-to-date to $55.9 million. Management has consistently emphasized revenue growth driven by soft tissue repair products and expanding market penetration, and the financials show delivering growth aligned with this priority.
“We continued to drive solid revenue growth in the second quarter of 2026 with net revenue of $28.1 million, representing a 9% increase over the second quarter of 2025.”
“We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability.”
Overall, SMTI's fundamentals show promise but are tempered by risks and mixed execution quality. Not investment advice.